Literature DB >> 15037206

Methioninase and selenomethionine but not Se-methylselenocysteine generate methylselenol and superoxide in an in vitro chemiluminescent assay: implications for the nutritional carcinostatic activity of selenoamino acids.

Julian E Spallholz1, Vince P Palace, Ted W Reid.   

Abstract

Methylselenol from selenium metabolism is postulated to be and most experimental evidence now indicates that it is the selenium metabolite responsible for the dietary chemoprevention of cancers. Using the recombinant enzyme methioninase, methylselenol-generating chemiluminesence by superoxide (O2*-) is shown to be catalytically produced from L-selenomethionine and D,L-selenoethionine, but not from methionine or L-Se-methylselenocysteine (SeMC). Methylselenol enzymaticaly generated by methioninase activity from the substrate selenomethionine arises from an initial putative selenium radical as measured by chemiluminesence in the absence of glutathione (GSH). In the presence of GSH, superoxide was generated as measured by chemiluminesence and superoxide dismutase inhibition of chemiluminescence. Ascorbic acid also quenched the chemiluminesence from the activity of methioninase with selenomethionine. Methylselenol and other redox cycling selenium compounds are almost assuredly accountable for inducing cell-cycle arrest and apoptosis in cancer cells in vitro and in vivo. Methylselenol generated from selenomethionine by methioninase is catalytic alone in oxidizing thiols, i.e. GSH, generating superoxide and inducing oxidative stress in direct proportion to its concentration. Se-methylselenocysteine in vivo is very likely carcinostatic in like manner to selenomethionine by generating methylselenol from other enzymatic activity, i.e. beta-lyase or amino acid oxidases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037206     DOI: 10.1016/j.bcp.2003.09.004

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  28 in total

1.  Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells.

Authors:  Rui Zhao; Frederick E Domann; Weixiong Zhong
Journal:  Mol Cancer Ther       Date:  2006-12       Impact factor: 6.261

2.  Selenium status and cardiovascular diseases: meta-analysis of prospective observational studies and randomized controlled trials.

Authors:  X Zhang; C Liu; J Guo; Y Song
Journal:  Eur J Clin Nutr       Date:  2015-05-20       Impact factor: 4.016

3.  Trans-sulfuration Pathway Seleno-amino Acids Are Mediators of Selenomethionine Toxicity in Saccharomyces cerevisiae.

Authors:  Myriam Lazard; Marc Dauplais; Sylvain Blanquet; Pierre Plateau
Journal:  J Biol Chem       Date:  2015-03-05       Impact factor: 5.157

4.  Serum selenium and serum lipids in US adults.

Authors:  Joachim Bleys; Ana Navas-Acien; Saverio Stranges; Andy Menke; Edgar R Miller; Eliseo Guallar
Journal:  Am J Clin Nutr       Date:  2008-08       Impact factor: 7.045

5.  Phenylalkyl isoselenocyanates vs phenylalkyl isothiocyanates: thiol reactivity and its implications.

Authors:  Melissa A Crampsie; Manoj K Pandey; Dhimant Desai; Julian Spallholz; Shantu Amin; Arun K Sharma
Journal:  Chem Biol Interact       Date:  2012-09-13       Impact factor: 5.192

6.  Analysis of Saccharomyces cerevisiae null allele strains identifies a larger role for DNA damage versus oxidative stress pathways in growth inhibition by selenium.

Authors:  Eden Seitomer; Bharvi Balar; Dongming He; Paul R Copeland; Terri Goss Kinzy
Journal:  Mol Nutr Food Res       Date:  2008-11       Impact factor: 5.914

7.  Serum selenium and peripheral arterial disease: results from the national health and nutrition examination survey, 2003-2004.

Authors:  Joachim Bleys; Ana Navas-Acien; Martin Laclaustra; Roberto Pastor-Barriuso; Andy Menke; Jose Ordovas; Saverio Stranges; Eliseo Guallar
Journal:  Am J Epidemiol       Date:  2009-02-16       Impact factor: 4.897

8.  Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease The SElenium Therapy in Coronary Artery disease Patients (SETCAP) Study.

Authors:  Renate Schnabel; Edith Lubos; Claudia M Messow; Christoph R Sinning; Tanja Zeller; Philipp S Wild; Dirk Peetz; Diane E Handy; Thomas Munzel; Joseph Loscalzo; Karl J Lackner; Stefan Blankenberg
Journal:  Am Heart J       Date:  2008-12       Impact factor: 4.749

9.  Serum selenium concentrations and diabetes in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004.

Authors:  Martin Laclaustra; Ana Navas-Acien; Saverio Stranges; Jose M Ordovas; Eliseo Guallar
Journal:  Environ Health Perspect       Date:  2009-05-15       Impact factor: 9.031

10.  Timing of supplementation of selenium and isoflavones determines prostate cancer risk factor reduction in rats.

Authors:  Jessica R Tolman; Edwin D Lephart; Kenneth Dr Setchell; Dennis L Eggett; Merrill J Christensen
Journal:  Nutr Metab (Lond)       Date:  2008-11-10       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.